Giant Gastrointestinal Stromal Tumor with Remarkable Preoperative Response to Imatinib Mesylate

The development of IM was featured on the cover of Time in May 2001, was touted as a revolutionary therapeutic agent for chronic myelogenous leukemia, and was later found to be effective in the control of GIS tumors. [...] its indication for use has been for patients with malignant metastatic or unr...

Full description

Saved in:
Bibliographic Details
Published inThe American surgeon Vol. 76; no. 8; pp. 903 - 904
Main Authors STOKES, Allen, HERNDON, Mark D, CONFORTI, Arnold M
Format Journal Article
LanguageEnglish
Published Atlanta, GA Southeastern Surgical Congress 01.08.2010
SAGE PUBLICATIONS, INC
Subjects
Antineoplastic Agents - therapeutic use
Benzamides
Biological and medical sciences
Gastroenterology. Liver. Pancreas. Abdomen
Gastrointestinal Stromal Tumors - drug therapy
General aspects
Humans
Imatinib Mesylate
Male
Medical sciences
Medical treatment
Middle Aged
Piperazines - therapeutic use
Pyrimidines - therapeutic use
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Tumors
Antineoplastic agent
Imatinib
Enzyme
Tyrosine kinase inhibitor
Transferases
Enzyme inhibitor
Gastrointestinal stromal tumor
Medicine
Treatment
Surgery
Digestive diseases
Intestinal disease
Preoperative
Protein-tyrosine kinase
Online AccessGet full text

Cover

More Information
Summary:The development of IM was featured on the cover of Time in May 2001, was touted as a revolutionary therapeutic agent for chronic myelogenous leukemia, and was later found to be effective in the control of GIS tumors. [...] its indication for use has been for patients with malignant metastatic or unresectable disease.1 Eisenberg et al. report that more than 80% of malignant metastatic or inoperable GIST have achieved a decrease in tumor burden of 50% or more (partial response) or had no disease progression. . .
ISSN:0003-1348
1555-9823
DOI:10.1177/000313481007600840